miRNA与小细胞肺癌关系的研究进展

Advances in the Relationship between miRNA and Small Cell Lung Cancer

小细胞肺癌(Small Cell Lung Cancer, SCLC)是一种恶性程度高的神经内分泌肿瘤,其病情进展快,短期内易出现耐药或复发,预后很差。微小RNA (microRNA, miRNA)是一类由19~25个核苷酸组成的非编码单链RNA,广泛分布于真核生物中,参与多种疾病的发生过程。有研究显示,miRNA在SCLC中表达失调,发挥抑癌或促癌作用,参与SCLC的增殖、侵袭、转移及耐药的生物学过程。同时,也有报道,miRNA作为SCLC的诊断及预后的生物标志物提供了可能性。本文就miRNA在SCLC的增殖转移、耐药、诊断、预后等相关的研究进展作一综述。

Small cell lung cancer (SCLC) is a highly malignant neuroendocrine tumor with rapid progression, short-term susceptibility to drug resistance or recurrence, and poor prognosis. MicroRNA (miRNA) is a class of non-coding single-stranded RNAs consisting of 19~25 nucleotides, which are widely distributed in eukaryotes and are involved in the process of many diseases. Some studies have shown that miRNAs are dysregulated in SCLC expression, exert oncogenic or pro-oncogenic effects, and participate in the biological processes of proliferation, invasion, metastasis, and drug resistance in SCLC. Meanwhile, it has also been reported that miRNAs offer possibilities as biomarkers for the diagnosis and prognosis of SCLC. In this paper, we present a review of the research progress of miRNAs related to proliferation and metastasis, drug resistance, diagnosis and prognosis of SCLC.